TD Asset Management
ACOR

TD Asset Management’s Acorda Therapeutics ACOR Stock Holding History

TD Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-176
Closed -$443K – 1388
2017
Q1 		$443K Buy
176
+25
+17% +$72K ﹤0.01% 1241
2016
Q4 		$340K Sell
151
-47
-24% -$112K ﹤0.01% 1273
2016
Q3 		$495K Buy
+198
New +$591K ﹤0.01% 1187
2015
Q3 		– Sell
-85
Closed -$340K – 1395
2015
Q2 		$340K Hold
85
– – ﹤0.01% 1224
2015
Q1 		$339K Buy
85
+17
+25% +$77.9K ﹤0.01% 1212
2014
Q4 		$331K Hold
68
– – ﹤0.01% 1205
2014
Q3 		$274K Hold
68
– – ﹤0.01% 1178
2014
Q2 		$273K Sell
68
-8
-11% -$32.6K ﹤0.01% 1159
2014
Q1 		$345K Buy
76
+8
+12% +$32.3K ﹤0.01% 1123
2013
Q4 		$237K Hold
68
– – ﹤0.01% 1190
2013
Q3 		$278K Buy
68
+9
+15% +$38.8K ﹤0.01% 1132
2013
Q2 		$234K Buy
+59
New +$243K ﹤0.01% 1099

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TD Asset Management's ACOR Position: Q2 2017 in Review

TD Asset Management sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 176 shares — an estimated $443K sold.

TD Asset Management first reported a position in ACOR in Q2 2013 and held it in 12 quarters. The position peaked at $495K in Q3 2016. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • TD Asset Management reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • TD Asset Management sold 176 Acorda Therapeutics shares in Q2 2017, an estimated $443K.
  • TD Asset Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 12 quarters.
  • TD Asset Management's Acorda Therapeutics position peaked at $495K in Q3 2016.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on TD Asset Management's 13F filing for Q2 2017, filed 1 Aug 2017.